期刊文献+

磷霉素氨丁三醇与环丙沙星随机对照治疗急性细菌性泌尿道感染的评价 被引量:5

Randomized-controlled Clinical Trial on Fosfomycin Trometamal Versus Ciprofloxacin in the Treatment of Urological Tract Bacterial Infections
在线阅读 下载PDF
导出
摘要 目的 :用磷霉素氨丁三醇与环丙沙星随机对照治疗急性细菌性泌尿道感染 ,对前者进行安全性及有效性评价。方法 :磷霉素氨丁三醇 3g,QD ,疗程 5天 ,环丙沙星 2 5 0mgBid ,疗程 5天。结果 :共完成 41例 (试验组 2 1例 ,对照组 2 0例 ) ,病种包括急性膀胱炎、急性尿道炎、急性肾盂肾炎、慢性肾盂肾炎急发、复杂尿路感染。试验组与对照组对不同感染病种患者的有效率分别为 95 2 4%与 90 0 0 % ;与两组不同细菌感染者的有效率相似 ,无显著性差异 (P >0 0 5 ) ,两组细菌清除率分别为 10 0 %与 94 44 % ,不良反应发生率分别为 4 76 %与5 0 0 % ,差异无显著性 (P >0 0 5 )。 36株细菌对磷霉素氨丁三醇与环丙沙星敏感率为 77 77%与 75 0 0 %。结论 :磷霉素氨丁三醇抗菌谱广 ,抗菌活性强 ,为一治疗急性细菌性泌尿道感染安全有效的口服药物。 Objective:The efficacy and safty of fosfomycin trometamal versus ciprofloxacin were evaluated through randomized controlled clinical trials on patients with acute urological tract bacterial infections.Method:Twenty-one patients enrolled in trial group and received fosfomycin trometamal 3g QD for 5days;20 in control groups received I ciprofloxacin 250mg Bid for 5 days.Results:The efficacy rate in each group were 95 24% and 90 00%,bacterial eradication rate were 100% and 94 44%,92 31%,adverse events rate were 4 76% and 5 00% respectively.There were no significant differences between the relavant rates ( P >0 05).The sensititvity rate of bacterial isolates to fosfomycin trometamal and ciprofloxacin were 77 77% and 75 00%,mildly higher than that of ciprofloxacin.Conclusion:The results suggested that fosfomycin trometamal with wide antibacterial spectrum,satisfactory activity,is an effective and safe antibiotics in treatment of mild to moderate acute ,urological tract bacterial infections.[WT5”HZ]
出处 《华西医学》 CAS 2000年第2期172-175,共4页 West China Medical Journal
关键词 磷霉素氨丁三醇 环丙沙星 随机对照 泌尿道感染 Fosfomycin trometamal Ciprofloxacin Randomized-controlled Clinical trial Urological tract infection.
  • 相关文献

参考文献2

  • 11,Minassian MA,Williams JD,The clinical pharmacologyof fosfomycin trometamol.Rev Contemp Pharmacother,1995;6(2)∶4588.
  • 22,San jay SP,Julia AB,Harrier MB.Fosfomycin tromethamine.Drugs,1997;38∶853. (

同被引文献26

  • 1王明贵.喹诺酮类抗菌药的耐药性及质粒介导耐药机制[J].中华医学杂志,2006,86(9):645-647. 被引量:35
  • 2胡辉,张永信.磷霉素氨丁三醇的临床评价[J].世界临床药物,2007,28(2):79-82. 被引量:9
  • 3[2]National Committee for Clinical Laboratory Standars. Performance standards for antimicrobial susceptibility testing [S]. Ninth informational supplement NCCLS, 1999,19: M100-S9
  • 4[3]Garau M,Latorre A,Alonso-Sanz M. Fosfomycin: an underrated antibiotic for urinary tract infections due to Escherichia coli[J].Enferm Infecc Microbiol Clin, 2001,19: 462-466
  • 5[4]Greenwood D,Edwards R,Brown J, et al. The comparative activity of fosfomycin trometamol against organisms isolated from infected urines[J]. Infection, 1992,20 (Suppl 4): S302-304
  • 6European Pharmacopoeia Commission. European Pharmacopoeia (8. 0 版) [ S]. European Directorate for the Quality of Medicines( EDQM), 2013.
  • 7MARAKI S, SAMONIS G, RAFAILIDIS PI ,et al. Susceptibility ofurinary tract bacteria to fosfomycin [ J ]. Antimicrob AgentsChemother,2009,53(10) :4508.
  • 8BUTCU M,AKCAYSS,LNAN AS. et al. In vitro susceptibility ofenterococci strains isolated from urine samples to fosfomycin andother antibiotics[ J]. J Infect Chemother,2011,17 (4) :575.
  • 9RAZ R. Fosfomycin: an old-new antibiotic [ J ]. Clin MicobiolInfect,2012,18(l) :4.
  • 10FALAGAS ME,MARKI S,KARAGEORGOPOULOS DE’et al.Antimicrobial susceptibility of multdrug-resitant ( MDR ) andextesively drug-resitant ( XDR ) Enterobacteriaceae isolates tofosmycin[ J]. Int J Antimicrob Agents,2010,35 (3 ) :240.

引证文献5

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部